Inclusion Criteria:

- Patients with histologic proof of LCH who have multifocal or multisystem disease
involvement.

- Patients must have a life expectancy of at least 8 weeks.

- All patients must have ECOG performance level rating of-< 2.

- Patients or their parents (guardian) must sign an informed consent indicating that
they are aware of the investigational nature of the study, using commercially
available drugs.

- Patients must have recovered from the toxic effects of prior therapy before entering
this study or at least 2 weeks should have elapsed since the end of last course of
chemotherapy.

- Patients must have adequate liver function (bilirubin _< 2.0 mg/dl, SGOT less than
1.5 times normal (unless it is due to disease), adequate renal function (creatinine
<_ 1.5 mg/dl, creatinine clearance >_ 60 ml/min/1.73 m2) and normal electrolytes.

- Patients should have a granulocyte count > 500/uL and a platelet count >_ 100,000/uL
(unless due to disease involvement of the bone marrow).

- Male and female patients of child-bearing age should use effective methods of
contraception, if sexually active.

Exclusion Criteria:

- Patients with active infections or significant medical conditions other than their
disease (LCH) shall be excluded.